Please login to the form below
AZ to sell Astra Tech for $1.8bn
AstraZeneca is to sell Sweden-based dental and devices business Astra Tech to Dentsply for $1.8bn
AstraZeneca (AZ) is to sell Sweden-based dental and devices business Astra Tech to Dentsply for $1.8bn.
Dentsply, a US-based dental equipment maker, is anticipated to complete the acquisition in the second half of 2011.
Astra Tech consists of a dental division, focusing on the research, development, manufacturing and marketing of dental implants; and a healthcare division, focusing on medical devices for use primarily in urology and surgery.
Worldwide revenue for Astra Tech was recorded as $535m for 2010.
"Following a comprehensive strategic review, we believe this transaction represents an excellent outcome for AstraZeneca shareholders," said David Brennan, CEO, AZ. "The high degree of interest and the competitive nature of this process is evidence of the value that the employees of Astra Tech have built in the marketplace."
Share
Related Hub content
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
